Events

George Georgiou is the Dula D. Cockrell Centennial Chair and Professor at UT Austin, Depts of Chemical Engineering, Molecular Biosciences and Biomedical Engineering, as well as Dept of Oncology DMS.  He has authored >300 publications and is co-inventor of >170 issued and pending US patents.  He is an elected member of the National Academy of Engineering (2005), National Academy of Medicine (2011), National Academy of Inventors (2015) and the American Academy of Arts and Sciences (2015) and several other honorary societies.  Dr. Georgiou founded GGMJD (acquired), Aeglea Biotherapeutics (NSDQ: SYRE) and Ikena Oncology in 2016 (NSDQ: IKNA).  He served on the Board of Directors of AGLE (2013-18) and IKNA (2016-2021).  He is co-inventor and led the early development of marketed therapeutics olbitoxaximab and pegzilarginase, clinical stage pegtarviliase and several mid- to late-stage preclinical drugs. 

Dr. Georgiou’s research is focused on: (i) the molecular level understanding of human adaptive immunity in infectious diseases and in autoimmunity; (ii) the discovery/preclinical development of enzyme and antibody therapeutics and (iii) the biology of antibody receptors and the engineering of next-generation of therapeutic antibodies with improved pharmacological properties.